Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling

Radiation therapy (RT) provides therapeutic benefits for patients with glioblastoma (GBM), but inevitably in-duces poorly understood global changes in GBM and its microenvironment (TME) that promote radio -resistance and recurrence. Through a cell surface marker screen, we identified that CD142 (tissue factor or F3) is robustly induced in the senescence-associated b-galactosidase (SA-bGal)-positive GBM cells after irradiation. F3 promotes clonal expansion of irradiated SA-bGal+ GBM cells and orchestrates oncogenic TME remodeling by activating both tumor-autonomous signaling and extrinsic coagulation pathways. Intratumoral F3 signaling induces a mesenchymal-like cell state transition and elevated chemokine secretion. Simultaneously, F3 -mediated focal hypercoagulation states lead to activation of tumor-associated macrophages (TAMs) and extracellular matrix (ECM) remodeling. A newly developed F3-targeting agent potently inhibits the aforementioned oncogenic events and impedes tumor relapse in vivo. These findings support F3 as a critical regulator for therapeutic resistance and oncogenic senescence in GBM, opening potential therapeutic avenues.